An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.
A closely watched clinical study involving Merck & Co. Inc.’s anti-PD-1 therapy Keytruda (pembrolizumab) has reported promising results at an interim analysis, in combination with chemotherapy as a first-line therapy for metastatic triple-negative breast cancer.
The pivotal Phase III KEYNOTE-355 study met one of its dual primary endpoints, improving progression-free survival in metastatic triple-negative breast...
Create an account to read this article
Already a subscriber?
With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.
The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.
The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.
Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.
Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.
The agency’s approval of Imfinzi combined with chemotherapy makes it the only immunotherapy for perioperative gastric and gastroesophageal cancers.
Satellos is moving to start a double-blinded Phase II trial of its experimental Duchenne muscular dystrophy candidate that looks to mimic the effects of dystrophin on muscle stem cells.
